['systemic lupus erythematosus (sle)']
['placebo', 'dapirolizumab pegol (dzp)']

        Inclusion Criteria:

          -  Clinical diagnosis of Systemic Lupus Erythematosus (SLE) confirmed by Systemic Lupus
             International Collaborating Clinics (SLICC) classification criteria

          -  Moderate to severe SLE disease activity

          -  Evidence for at least 1 of the following SLE markers:

               -  Anti-dsDNA antibodies confirmed by central laboratory or

               -  Low complement confirmed by central laboratory or

               -  Antinuclear antibody (ANA) titer of >= 1:80 in combination with at least 1 of the
                  following: Historical positivity for anti-dsDNA or Positivity for extractable
                  nuclear antigen (anti-ENA) confirmed by central laboratory

          -  The subject is receiving stable SLE standard-of-care medication

        Exclusion Criteria:

          -  Mixed connective tissue disease, scleroderma, and/or overlap syndromes of SLE

          -  Subjects with severe neuropsychiatric SLE or other neurological symptoms that in the
             opinion of the Investigator, would prevent the subject from completing protocol
             required procedures and assessments.

          -  New or worsening Class III or IV lupus nephritis

          -  Chronic kidney failure stage 3b

          -  Evidence of human immunodeficiency virus (HIV) infection, agammaglobulinemias, T-cell
             deficiencies, or human T-cell lymphotropic virus-1 infection at any time prior to or
             during the study

          -  Clinically significant active or latent infection (eg. chronic viral hepatitis B or C)

          -  Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent
             TB (LTB) infection

          -  Live/live attenuated vaccines within 6 weeks prior to the first study drug infusion
             (Visit 2) or who plan to receive these vaccines during the study or 12 weeks after the
             final dose of study drug

          -  History of thromboembolic events within 12 months of screening

          -  Subject has used protocol defined prohibited medications
      